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Background: The role of dietary antioxidants and plasma oxidant-antioxidant status in low-29 
grade chronic inflammation and adipocytokine levels is not established yet. 30 
Objectives: We aimed to evaluate whether total dietary antioxidant capacity (assessed by dietary 31 
ferric reducing antioxidant potential (FRAP)), serum uric acid (UA) and gamma 32 
glutamyltransferase (GGT) were associated with low-grade chronic inflammation and circulating 33 
adipocytokines.  34 
Methods: Data of 4,506 participants aged ≥55 years from the Rotterdam Study were analyzed. 35 
Baseline (1990-1993) FRAP score was assessed by a food frequency questionnaire. Baseline UA 36 
and GGT levels were assessed in non-fasting serum samples.  Serum high sensitivity C-reactive 37 
protein (hs-CRP) was measured at baseline and 10 years later. Plasma leptin, adiponectin, 38 
plasminogen activator inhibitor-1 (PAI-1) and resistin levels were assessed 10 years later.  39 
Results: A high FRAP score was associated with lower levels of UA and GGT. Overall, no 40 
association was found between FRAP and hs-CRP levels. FRAP score was associated with lower 41 
levels of leptin and PAI-1, higher levels of adiponectin, and no difference in resistin levels. 42 
Increased levels of UA were associated with higher levels of hs-CRP, PAI-1 and leptin; lower 43 
levels of adiponectin and no difference in resistin levels. Similarly, GGT was associated with 44 
higher levels of hs-CRP whereas no association was observed between GGT and adipocytokines.  45 
Conclusion: These findings suggest that overall antioxidant capacity of diet and low levels of 46 
UA are associated with circulating adipocytokines whereas no consistent association was found 47 
with hs-CRP. 48 
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1. INTRODUCTION 53 
Low-grade chronic inflammation has been involved in the pathogenesis of atherosclerosis and 54 
development of coronary heart disease (CHD) [1, 2]. C-reactive protein (CRP), an acute phase 55 
reactant, is a general marker of low-grade chronic inflammation and has been associated with 56 
markers of atherosclerosis and CHD [2-4]. Plasma sensitive CRP (hs-CRP) correlates with 57 
obesity and obesity-related disorders, including insulin resistance and type 2 diabetes [5]. 58 
Adipose tissue synthesizes and releases many inflammatory mediators into the systemic 59 
circulation termed adipocytokines, and include leptin, adiponectin, plasminogen activator 60 
inhibitor-1 (PAI-1) and resistin, all of which can initiate the development of chronic 61 
inflammation and may directly contribute to metabolic and vascular diseases [6-15].  62 
An imbalance between plasma oxidants-antioxidants (oxidative stress) as well as dietary 63 
antioxidants have been suggested to play a role in systemic low-grade chronic inflammation [16]. 64 
Oxidative stress, defined as an increased load of free radicals, induces the activation of NF-κB, a 65 
transcription factor involved in cell survival, differentiation, and inflammation [17]. Antioxidant 66 
molecules neutralize such free radicals and therefore diminish low-grade inflammation. Dietary 67 
antioxidants, including vitamin A, E and C, can counteract oxidative stress and therefore its 68 
adverse effect on inflammation [18]. However, studies evaluating the role of individual 69 
antioxidants on inflammation have shown contradictory results, which can be due to not taking 70 
into account the interactive effect among nutrients [19]. Hence, assessing the overall effects of 71 
antioxidants in the diet instead of the individual effects can provide further information regarding 72 
the association between diet and inflammation [19]. The ferric reducing antioxidant potential 73 
(FRAP) measures the overall antioxidant capacity of diet by measuring the reduction of ferric 74 
iron (Fe3+) to ferrous iron (Fe2+)[20] and, has been used as a marker of the overall effects of 75 
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antioxidants in many studies. FRAP has been associated with inflammatory related diseases, 76 
including cardiovascular disease and cancer [21, 22]. However, only a few studies have assessed 77 
its role on inflammation and adipocytokine levels [22-24]. Furthermore, serum levels of uric acid 78 
(UA) and gamma-glutamyl transferase (GGT) are considered endogenous markers of oxidative 79 
stress [25]. Both levels of UA and GGT positively correlate with markers of low-grade 80 
inflammation including hs-CRP, but how UA and GGT levels relate longitudinally with hs-CRP 81 
and adipocytokine levels remains unclear [26-29]. 82 
Therefore, we aimed to assess whether FRAP and endogenous markers of oxidative stress, UA 83 
and GGT, were associated with low-grade chronic inflammation and circulating adipocytokine 84 
concentrations in a prospective cohort of middle aged and elderly men and women. 85 
2. MATERIAL AND METHODS 86 
The study was performed within the Rotterdam Study (RS), a population-based cohort among 87 
individuals 55 years and over in the Ommoord district of Rotterdam, the Netherlands. The 88 
rationale and design of the RS is described elsewhere [30]. The baseline examination (RS-I) took 89 
place in 1990-1993. Trained research assistants collected data on medical history, current health 90 
status, use of medication, lifestyle and risk indicators for chronic diseases during an extensive 91 
home interview. Subsequently the participants visited the study center for detailed clinical 92 
examinations and assessment of diet. Follow up visits were held every 3-4 years.   93 
2.1 MEASUREMENTS 94 
2.1.1 Assessment of ferric reducing antioxidant potential (FRAP) 95 
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Dietary antioxidant capacity was assessed from the FFQ (Online Supplemental Material) the 96 
participants filled in during the interview. We used the Antioxidant Food Table published by the 97 
Institute of Nutrition Research, University of Oslo, which includes measurements of  >3,000 98 
foods [31], to calculate each food’s contribution to ferric reducing antioxidant potential. The 99 
FRAP assay assesses the antioxidant capacity of individual food items to reduce ferric iron (Fe3+) 100 
to ferrous iron (Fe2+) [20]. Since the food table consisted of foods from several manufacturers, 101 
we consulted nutritional experts at Wageningen University (the Netherlands) to determine the 102 
linkage of foods from several manufacturers that were closest to the Dutch food products. For 103 
each participant, we multiplied the consumption frequency of each food by the corresponding 104 
FRAP value (in mmol/100g), and summed these values across all dietary sources. Vitamin 105 
supplementation was not included in the FRAP assessment because there were no detailed data 106 
available. Most variation in dietary FRAP score was explained by intakes of coffee (65%) and 107 
tea (21%) as described previously[21].  108 
2.1.2 Assessment of Uric Acid and Gamma–glutamyltransferase (GGT)   109 
Values of serum UA and GGT were obtained from baseline (1990-1993) non-fasting blood 110 
samples, which were centrifuged and the serum was subsequently frozen (−20°C) for 1 week.  111 
UA was determined with a Kone Diagnostica reagent kit and a Kone autoanalyzer. In order to 112 
check the calibration, 3 control samples were included every 10 samples. If the average values of 113 
the control samples of each run (100 samples) were not within 2.5% of the true value, the run 114 
was repeated. Day-by-day variation had to be within 5% [32]. Serum GGT levels were 115 
determined within two weeks using a Merck Diagnostica kit (Merck, Whitehouse Station, NJ, 116 
USA) on an Elan Autoanalyzer (Merck). 117 
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2.1.3 Assessment of hs-CRP and adipocytokines  118 
hs-CRP was measured in non-fasting frozen serum of study participants at baseline (1990-1993) 119 
and at the third center visit (1997-1999). A rate near-infrared particle immunoassay (Immage 120 
Immunochemistry System, Beckman Coulter, Fullerton, CA, USA) was used. This system 121 
measures concentrations from 0.2 to 1440mg/l, with a within-run precision of 0.5%, a total 122 
precision <7.5% and a reliability coefficient of 0.995. Undetectable CRP was scored as 0.2 123 
(n=72).  124 
For assessment of adipocytokines, fasting blood samples were collected at the research center, in 125 
the third center visit (1997-1999). Plasma was isolated and immediately put on ice and stored at  126 
-80°C. Citrate plasma (200Ul) was sent in July 2008 to Rules-Based Medicine, Austin, Texas 127 
(www.myriadrbm.com). Fifty inflammatory biomarkers were quantified using multiplex 128 
immunoassay on a custom designed human multianalyte profile. The intra-assay variability was 129 
less than 4% and the inter assay variability was less than 13%. Biomarkers with more than 60% 130 
completeness of measurements were selected for imputation and further analysis. Data on leptin, 131 
adiponectin, plasminogen activator inhibitor 1 (PAI-1) and resistin, major inflammatory markers 132 
released by adipose tissue [7], were available. The inflammatory markers investigated in the 133 
current study have no standard international calibration reference therefore, interpretation of the 134 
absolute values should be with caution. Since the current study is conducted within one set of 135 
individuals, the use of relative measures should not affect the effect estimates. 136 
2.2 POPULATION FOR ANALYSIS 137 
 2.2.1 FRAP and inflammation 138 
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In the baseline examination (1990-1993) of the first cohort of the Rotterdam Study, 7,983 139 
participants were included. Of out 7,983 participants, 6,521 participants were invited for dietary 140 
intake interview, out of which only 5,435 (83%) participants completed food frequency 141 
questionnaire and therefore had complete information on dietary intake. Moreover, out of 7,983 142 
participants, randomly we invited 7,129 participants to assess cardiovascular risk factors, 143 
including CRP. However, only 6658 (93.3%) had C-reactive protein assessed. Participants with 144 
available information on both dietary and C-reactive protein levels were 5104. Further, we 145 
excluded 598 participants who reported use of anti-inflammatory drugs at baseline and/or during 146 
the follow-up (n=598), leaving 4,506 participants for the analysis of FRAP with CRP (Figure 1). 147 
In addition, leptin, adiponectin, PAI-1 and resistin were measured in a random subsample of 971 148 
participants, hence only 798 participants were included in the analysis of FRAP with 149 
adipocytokines (Figure 1). 150 
 2.2.2 Uric acid, gamma-glutamyltransferase and inflammation  151 
In the baseline examination (1990-1993) of the first cohort of the Rotterdam Study, 7,983 152 
participants were included. Uric acid and GGT data were available for 5,047 subjects (Figure 2). 153 
Out of these, 893 participants were excluded either because they did not have CRP measured at 154 
the first visit or because they reported use of anti-inflammatory drugs at baseline and/or during 155 
the follow-up, leaving 4,154 participants for the analysis of uric acid with CRP and GGT with 156 
CRP. 3,447 participants were further excluded because they did not have measures of other 157 
inflammatory markers, hence 707 participants were included in the analysis of uric acid and 158 
GGT with leptin, adiponectin, PAI-1 and resistin (Figure 2). 159 
2.3 STATISTICAL ANALYSES 160 
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Data are presented as mean (± standard deviation) for normally distributed continuous variables, 161 
median (range) for continuous variables that are not normally distributed, and percentages for 162 
categorical variables. We used natural log-transformed values of serum CRP concentrations, 163 
GGT, non-fasting serum glucose, leptin, adiponectin, PAI-1 and resistin to better approximate a 164 
normal distribution. Pearson correlations were used to assess the correlations between 165 
inflammatory markers. To account for systematic measurement error in FRAP, FRAP was 166 
adjusted for total energy intake by using the residual method in the analysis[33]. FRAP was 167 
analyzed continuously. For analyses evaluating CRP as outcome, we fitted linear regression 168 
models using generalized estimating equations with exchangeable correlation structure adjusting 169 
for the within-subject correlations due to the repeated measurements of CRP in the same 170 
individual (inter-class correlation coefficient = 0.682 for natural log-transformed CRP) [34]. 171 
Multivariable linear regression was used to examine whether FRAP, GGT and UA were 172 
independently associated with blood levels of adiponectin, leptin, resistin and PAI-1. Regression 173 
coefficients (βs) and 95% confidence intervals were obtained on the basis of robust standard 174 
errors (95% CI). First, we calculated age and gender adjusted coefficients (Model 1) for the 175 
following exposure: FRAP, GGT and UA. Subsequently in Model 2, we adjusted for potential 176 
confounders when the covariates changed the effect estimate by more than 10% in univariate 177 
models of each exposure with any of the outcomes assessed. The following potential 178 
confounding factors, were evaluated: body mass index (BMI) (continuous), energy intake 179 
(continuous), physical activity(continuous), smoking status (never or former, current), lipid 180 
lowering medication use (Yes, No), systolic blood pressure(continuous), total 181 
cholesterol(continuous), vitamin supplementation (Yes, No), hormone replacement therapy 182 
(HRT) ( Yes, No), prevalent chronic diseases (CVD or T2D) (yes, no), non-fasting blood 183 
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glucose(continuous), education (low, intermediate, high), income (low, intermediate, high), 184 
alcohol, energy-adjusted processed meat intake (continuous), energy-adjusted unprocessed meat 185 
intake (continuous), Dutch Healthy Diet index (DHDI)(continuous). For the analysis on leptin, 186 
adiponectin, PAI-1 and resistin as outcomes, we also adjusted for CRP in the first visit (1990-187 
1993) as a proxy of chronic inflammation at baseline as adipocytokines were measured only at 188 
the third round visit (1997-1999).  To check for non-linear relation, a quadratic term was tested 189 
in multivariable model 2. Since there is evidence that the association between diet antioxidants 190 
and inflammatory biomarkers differs by sex [35], we tested for statistical interaction by adding a 191 
product term in model 2. Furthermore, stratified analysis was performed and the results were 192 
presented for model 2. We further checked the association of FRAP with uric acid, and FRAP 193 
with GGT using multivariable linear regression models. We also performed sensitivity analyses 194 
(i) restricting all main analyses to participants with available information on all exposures and 195 
outcomes investigated (N=633), (ii) excluding participants with chronic diseases (CVD or T2D) 196 
and (iii) further adjusted for BMI change from first to the third visit. A P-value lower than 0.05 197 
was considered as statistically significant, but to account for multiple testing, we adjusted the p-198 
value from 0.05 to 0.0166 by applying the Bonferroni correction for the number of exposures 199 
studied (N=3). 200 
To adjust for potential bias associated with missing data we used multiple imputation procedure 201 
(N= 5 imputations). All analyses were done using SPSS statistical software (SPSS, version 21.0; 202 
SPSS Inc., Chicago, Illinois). 203 
3. RESULTS 204 
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The main characteristics of the study population are shown by gender in Table 1. FRAP score 205 
and GGT levels were lower in women compare to men (FRAP: 20.02±5.07 mmol/day vs. 206 
20.83±5.95 mmol/day; GGT: median 21 U/l, range 351U/l vs median 27U/l, range 576 U/l) 207 
whereas UA levels were higher in women (296.62±71.44 µmol/l vs. 352.88±74.40 µmol/l) 208 
(Table 1). CRP levels at baseline were slightly lower in women whereas no significant 209 
difference was observed in the CRP levels at the third visit (Table 1). Also, women had slightly 210 
higher BMI (26.55 vs. 25.68 kg/m2) and leptin levels (median: 14.0 vs 4.02 ng/mL) than men. 211 
Although the energy intake was lower in women (1796 vs. 2246.2 kcal/day), they had higher 212 
physical activity (89.45 vs 69.15 MET) as well as a healthier diet (DHDI: 31.95 vs. 27.95) than 213 
men. Among the adipocytokines, PAI-1 and leptin (r=0.466, p=0.01), PAI-1 and CRP (r=0.325, 214 
p=0.01), PAI-1 and adiponectin (r=-0.270, p=0.01), leptin and CRP (r=0.254, p=0.01) showed 215 
the highest correlation (Supplementary Table S1). Compared to subjects who did not have 216 
information on leptin, adiponectin, PAI-1 and resistin, subjects who had information on these 217 
inflammatory markers did not differ with respect to FRAP, but had higher levels of CRP, BMI, 218 
systolic blood pressure and higher prevalence of chronic disease (Supplementary Table S2). 219 
3.1 The association between FRAP score and inflammatory markers 220 
There was no association between FRAP and hs-CRP levels in the age and gender-adjusted 221 
model or multivariable model (Table 2). In the multivariable models, FRAP score was 222 
associated with lower levels of leptin (β=-0.01, 95%CI=-0.02; -0.001), PAI-1 (β=-0.02, 95%CI=-223 
0.03; -0.01) and higher levels of adiponectin (β=0.01, 95%CI=0.002; 0.015). No association was 224 
observed between FRAP and resistin.  (Table 2).  225 
3.2 The association between UA, GGT and inflammatory markers 226 
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After multivariable adjustment, increased levels of UA were associated with higher levels of hs-227 
CRP (β=0.12, 95%CI=0.09; 0.16), leptin (β=0.10, 95%CI=0.05; 0.15) PAI-1 (β=0.15, 228 
95%CI=0.09; 0.20), and lower levels of adiponectin (β=-0.07, 95%CI=-0.10; -0.03) (Table 3). 229 
No association was observed between UA and resistin (Table 3). Similarly, after correcting for 230 
confounding factors, GGT was associated with higher levels of hs-CRP (β=0.06, 95%CI=0.13; 231 
0.19) whereas no association was observed between GGT and adipocytokines (Table 3).  232 
3.3 Effect modification by gender  233 
A significant effect modification by sex was found for the association between FRAP score and 234 
hs-CRP (P-interaction= 0.009). After stratification, a high dietary FRAP score was associated 235 
with lower levels of hs-CRP in women (β=-0.01, 95%CI=-0.02; -0.003), whereas no association 236 
was observed in men (Supplementary Table S3). No effect modification by sex was observed 237 
for the association between FRAP score with the adipocytokine levels (All P-interaction > 0.05). 238 
Similarly, the analyses were not different between strata of sex (Supplementary Table S3). 239 
Also, no sex differences were observed for the association of UA and GGT with CRP and 240 
adipocytokines (All P-intercation > 0.05) (Supplementary Table S4).  241 
 3.4 Sensitivity analyses  242 
Higher levels of FRAP score were associated with lower levels of both UA (β=-0.003, 95%CI=-243 
0.005; -0.002) and GGT (β=-0.006, 95%CI=-0.009; -0.003), after correcting for confounders 244 
(Supplementary Figure S1 and Supplementary Table S5). There was no evidence against a 245 
linear relation in all the main analyses (all P-values for quadratic term >0.05, data not shown). 246 
Also, all associations that were statistically significant in the main analyses remained unchanged 247 
in terms of statistical significance when the analyses were restricted to (i) participants with 248 
14 
 
available measures of FRAP, UA, GGT, CRP, leptin, adiponectin, PAI-1 and resistin (n=633) 249 
(data not shown), (ii) to subjects without chronic diseases (Supplementary Table S6 and S7) or 250 
(iii) when we further adjusted for changes in BMI between the first and third visit (data not 251 
shown).  The associations of FRAP with adiponectin and PAI-1, of UA with hs-CRP, leptin, 252 
adiponectin, and PAI-1, and the association of GGT with hs-CRP, remained significant after we 253 
applied the Bonferroni correction (all p<0.0166). 254 
4. DISCUSSION 255 
Overall a higher FRAP score was associated with leptin, adiponectin, and PAI-1 but not with 256 
CRP levels. Furthermore, increased levels of both GGT and UA levels were associated with 257 
higher levels of pro-inflammatory markers and lower levels of anti-inflammatory markers.  258 
In the current investigation, no association was found between FRAP and CRP levels in the 259 
overall population, however, in women, a higher FRAP score was associated with diminished 260 
chronic inflammation. Similar to our findings, Detopoulou et al  in a cross-sectional study of 532 261 
men and women found no association between FRAP and CRP levels in the total population 262 
[36]. In contrast, a cross-sectional study from Brighenti et al [23] , which used the TAC assay to 263 
measure antioxidant capacity, showed an association with lower levels of CRP in an adult Italian 264 
population including both men and women. We did find an interaction with gender, suggesting 265 
that the association between FRAP and CRP levels is present only in women, which is in line 266 
with the results of previous studies conducted in women. For example, the study from Kobayashi 267 
at al.[24] showed that dietary total antioxidant capacity was associated with lower serum CRP 268 
concentrations in young Japanese women (474 women, aged 18-22 years) regardless of assay 269 
used to measure it. Also, in a 9-month observational study among postmenopausal women, 270 
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Wang and his colleagues showed that consumption of diets rich in total antioxidants was 271 
associated with lower plasma CRP levels [37].  272 
Several studies show a stronger defense against oxidative damage in the female liver tissue, 273 
which is the major determinant of CRP levels [38]. Animal studies have shown that, compared to 274 
males, antioxidant capacity of diet assessed by FRAP and other methods is higher in liver tissue 275 
[38]. Also, females have greater mean hepatic alpha-tocopherol levels, total capacity of the 276 
cellular systems that detoxify reactive oxygen species or free radical-drug metabolites seems to 277 
be higher in the female rat liver[39]. These evidence may account for the sex differences 278 
observed in the association between FRAP and CRP levels in our study, which merits further 279 
investigation.  280 
Similar to our findings, previous studies [27, 40] have shown that increased UA levels are 281 
significantly associated with increased hs-CRP levels. Also in a study of Park et al [41] in 282 
postmenopausal women uric acid was associated with lower adiponectin levels. Another study 283 
from Ali et al [42] found that high GGT levels are associated with high hs-CRP levels 284 
implicating that elevated GGT levels are associated with burden of subclinical vascular 285 
inflammation. 286 
To our knowledge, this is the first study to show that the FRAP score was a determinant of leptin 287 
and PAI-I concentrations. In line with our findings, a previous study has shown an association 288 
between FRAP score and higher adiponectin levels [36]. Previous studies [43] have indicated 289 
that total antioxidant capacity of diet is associated with less central adiposity, as well as to 290 
metabolic (e.g. insulin resistance index) and oxidative stress markers in healthy young adults 291 
(e.g. oxidized-LDL, malondialdehyde). Central adiposity, mainly abdominal adiposity is the 292 
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main producer of anti-inflammatory (adiponectin) and pro-inflammatory markers (leptin, resistin 293 
and PAI-1)[12, 44, 45]. Leptin is an adipocyte-derived hormone that reduces food intake and 294 
increases energy expenditure by acting in the hypothalamus [46, 47] and has also pro-295 
inflammatory effects [7, 8]. Leptin levels correlate with higher indices of adiposity, however, 296 
individuals with similar degrees of adiposity have variations in serum leptin levels [46, 48]. 297 
Adiponectin is one of the most abundant adipocyte-derived hormones and appears to improve 298 
insulin sensitivity and vascular inflammation through its actions in liver and muscle [7]. Several 299 
studies have demonstrated that adiponectin is a marker and a mediator of metabolic risk, 300 
including the risk for conversion to diabetes and risk of myocardial infarction [49]. PAI-1, is 301 
another hormone secreted from fat cells, and is suggested to be a possible contributor to obesity-302 
induced diabetes and atherosclerosis [50]. Resistin, on the other hand, is almost an exclusively 303 
white adipose tissue-expressed polypeptide, and has also been linked to energy homeostasis and 304 
diet-induced obesity, insulin resistance and diabetes[51]. Other factors, including hormonal and 305 
nutritional factors have been suggested to influence concentrations of these inflammatory 306 
markers[52]. Our study also indicates that the antioxidant diet, GGT and UA may affect the 307 
levels of leptin, adiponectin, and PAI-I but not resistin independent of obesity. It was reported 308 
that uric acid induces CRP expression by implication on cell proliferation and nitric oxide 309 
production of human vascular cells [53]. Elevation of serum GGT is involved in the 310 
inflammatory response. It is plausible that elevation in GGT might occur before elevation in 311 
CRP, if oxidative stress leads to an inflammatory response [54]. These data imply that 312 
inflammation may be one of the underlying mechanism linking an antioxidant diet, GGT and UA 313 
with cardiometabolic outcomes, which needs to be elucidated by future studies. However future 314 
studies are needed to clarify specific inflammatory markers that may be involved in the pathway.   315 
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Probably oxidative stress is the pathway that links antioxidants with a low inflammatory profile. 316 
The human body has a number of defense mechanisms against oxidative stress including 317 
antioxidants, preventive and repair mechanism and physical defense [17]. Antioxidants 318 
themselves can be divided into enzymatic antioxidants (glutathione peroxidase, peroxide 319 
dismutase and catalase) and non-enzymatic antioxidants like ascorbic acid (vitamin C), alpha-320 
tocopherol (vitamin E), carotenoids, flavonoids. Coffee and tea are the main contributors of 321 
FRAP in Rotterdam Study and in other studies as well [21, 55]. The anti-inflammatory effects of 322 
both coffee and tea have been previously reported [56]. On the other hand, the anti-inflammatory 323 
effect of fruits and vegetables is supposed to come from vitamins and flavonoids they contain 324 
[19]. Antioxidants act scavenging ROS and inhibit NF-κβ, even though not all at the same level. 325 
This may lead to decreased oxidative stress, and therefore in diminished low-grade chronic 326 
inflammation. 327 
Our study is unique among previous investigations because of its prospective design, large 328 
population-based study group and adjustment for a broad range of confounders. Also, to our 329 
knowledge, this is one of the first prospective studies to use measures of CRP in two time points. 330 
Also, in our study, we could assess the association between FRAP and markers of oxidative 331 
stress, such as GGT and UA, showing a strong association, and therefore supporting internal 332 
validity. Nevertheless, it has some limitations. First, assessment of diet was done at baseline and 333 
there may have been changes in antioxidant consumption over time. However, it has been shown 334 
that dietary habits change very little over time in middle-aged adults [57]. Second, the FFQ can 335 
be limited by errors in reporting and recall and by incomplete assessment of all sources of 336 
antioxidant intake, which may introduce misclassification in dietary intake and would bias 337 
results toward the null. Third, we did not have repeated measures for leptin, adiponectin, PAI-1 338 
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and resistin. Also, these markers were assessed 10 years later from FRAP, UA and GGT 339 
measurements. Moreover, we had no measurements of other adipocyte-derived inflammatory 340 
markers like interleukin-6 or tumor necrosis factor-α or more accurate measures of oxidative 341 
stress such as ROS, that could have strengthened the results. Furthermore, we used a 342 
subpopulation for the analysis regarding adiponectin, resistin, leptin and PAI-1 as outcome, 343 
which may have introduced selection bias since this population was different with respect to 344 
some health characteristics. However, it has been shown that using a restricted source population 345 
for a cohort study usually leads to bias towards the null which may have led to an 346 
underestimation of the observed associations in our study of the exposure[58]. Moreover, it has 347 
been shown that using a selected source population for a cohort study usually leads to bias 348 
towards the null.  Furthermore, the restriction of the main analysis in the participants with 349 
available information on all exposures and outcomes investigated in this study provided similar 350 
results, and therefore, selection bias is less likely to have happened. Finally, physical activity was 351 
measured at the third round of the Rotterdam Study. Therefore, we cannot fully exclude residual 352 
confounding by physical activity levels. 353 
5. CONCLUSIONS 354 
In conclusion, we found no consistent association between FRAP and CRP levels, while both 355 
UA and GGT were associated with low CRP. Furthermore, high overall dietary antioxidant 356 
capacity of diet and lower levels of UA were associated with lower levels of pro-inflammatory 357 
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Figure 1: Flow chart of participants included in the analysis of overall antioxidant capacity of 530 
















FRAP, ferric reducing antioxidant potential; PAI-1, Plasminogen activator inhibitor-1;  547 
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Figure 2: Flow Chart of participants included in the analysis of uric acid and gamma-548 



































FRAP (mmol/day) 20.37±5.48 20.02±5.07 20.83±5.95 <0.001 
Age (years) 67.64±7.74 67.93±8.01 67.26±7.36 0.004 
Energy intake (kcal/day) 1989.51±504.48 1796.30±405.97 2246.17±508.24 <0.001 
Physical activity  
(MET hours/week) 
78.30±44.28 89.45±43.90 69.15±41.56 <0.001 
BMI (kg/m2) 26.18±3.57 26.55±3.99 25.68±2.85 <0.001 
CRP first rounda (mg/ml) 1.78 (0.86-3.39) 1.74 (0.85-3.13) 1.85 (0.87-3.79) <0.001 
CRP third rounda (mg/ml) 2.34 (1.16-4.34) 2.36 (1.15-4.26) 2.30 (1.16-4.46) 0.583 
Non-fasting serum glucosea 
(mml/l) 
6.20 (5.45-7.40) 6.10 (5.40-7.10) 6.40 (5.60-7.70) <0.001 
SBP (mmHg) 183.84±22.05 139.10±22.22 138.50±21.83 0.363 
DBP (mmHg) 78.80±11.26 73.29±11.14 74.47±11.39 <0.001 
Total Cholesterol (mmol/l) 6.68±1.19 6.92±1.18 6.35±1.12 <0.001 
Hormone replacement therapy,  
n (%) 
65 (1.4%) 63 (2.5%) 2 (0.1%) <0.001 
28 
 
Uric Acid (µmol/l) 320.16±77.76 296.62±71.44 352.88±74.40 <0.001 
Vitamin supplement use, n (%) 329 (7.3%) 245 (9.5%) 84 (4.3%) <0.001 
GGTa (U/l) 23.00 (18.00-32.00) 21.00 (16.00-28.00) 27.00 (21.00-38.00) <0.001 
Lipid reducing agents, n (%) 119 (2.6%) 66 (2.6%) 53 (2.7%) 0.395 
DHDI 30.23±9.20 31.95±9.11 27.95±8.83 <0.001 
Prevalent diseases*, n (%) 1490 (33.1%) 712 (27.7%) 778 (40.2%) <0.001 
Smoking:  Never or former, n (%) 3440 (76.3%) 2079 (80.9%) 1361 (70.3%) <0.001 
Current, n (%) 1066 (23.7%) 492 (19.1%) 574 (29.7%)  
Income:  Low, n (%) 1014 (22.5%) 829 (32.2%) 185 (9.6%) <0.001 
Middle, n (%) 2002 (44.4%) 1062 (41.3%) 940 (48.6%)  
High, n (%) 1490 (33.1%) 680 (26.4%) 810 (41.9%)  
Education: Low, n (%) 2321 (51.5%) 1597 (62.1%) 724 (37.4%) <0.001 
Middle, n (%) 1781 (39.5%) 862 (33.5%) 919(47.5%)  
High, n (%) 404 (9.0%) 112 (4.4%) 292 (15.1%)  
Processed meat intake 
(servings/day) 
1.47±1.24 1.19±1.05 1.84±1.37 <0.001 
     
29 
 
Unprocessed meat intake 
(servings/day) 
0.74±0.47 0.69±0.42 0.82±0.53 0.048 
Alcohol#:    <0.001 
Quartile I (<0.1886g), n (%) 1126 (25.0%) 847 (32.9%) 279 (14.4%)  
Quartile II (0.1886-3.6813g),  
n (%) 
1127 (25.0%) 798 (31.0%) 329 (17.0%)  
Quartile III (3.6813-15.1401g),  
n (%) 
1127 (25.0%) 572 (22.2%) 555 (28.7%)  
Quartile IV (>15.1401g), n (%) 1126 (25.0%) 354 (13.8%) 772 (39.9%)  
Leptinc (ng/mL) 7.63 (3.82-16.20) 14.00 (7.85-22.00) 4.02 (2.44-6.64) <0.001 
Adiponectinc (µg/mL) 3.42 (2.25-5.00) 4.34 (3.17-5.89) 2.7 (1.94-3.63) <0.001 
PAI-1c (ng/mL) 17.15 (9.98-28.63) 17.90 (10.30-33.20) 16.10 (9.66-26.15) 0.009 
Resistinc (ng/mL) 0.42 (0.31-0.58) 0.42 (0.31-0.58) 0.43 (0.31-0.59) 0.951 
FRAP, ferric reducing antioxidant potential; BMI, Body mass index; CRP, C-reactive protein; 574 
DHDI, Dutch healthy diet index (excluding fruits and vegetables); DBP, diastolic blood pressure; 575 
GGT, Gamma glutamyltransferase; PAI-1, Plasminogen activator inhibitor - 1; SBP, systolic 576 
blood pressure 577 
a Median (Range between 25th percentile and 75th percentile) 578 
b Comparison between men and women. For continuous variables = Independent sample T-Test; 579 
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For categorical variables = Chi2 (χ 2) 580 
c N=798 included in the analyses of FRAP and adipocytokines. 581 
*Prevalent disease include cardiovascular disease and type 2 diabetes. 582 
# Quartile I refers to values < 25th percentile; Quartile II refers to values between 25th and 50th 583 
percentile; Quartile III refers to values between 50th and 75th percentile; Quartile IV refers to 584 
values >75th percentile. 585 
  586 
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Table 2 Association of ferric reducing antioxidant potential with C-reactive protein and 587 
adipocytokines: the Rotterdam Study. 588 
CI, confidence interval; FRAP, ferric reducing antioxidant potential;  CRP, C-reactive protein; 589 
PAI-I, Plasminogen Activator Inhibitor-1. 590 
§ Variables were log transformed to better approximate normal distribution. 591 
*remains significant after Bonferroni correction (p=0.0166) 592 
βs and 95% confidence intervals were estimated using generalized estimated equations (for C-593 
reactive protein as outcome) and linear regression models (for leptin, adiponectin, PAI-1 and 594 
resistin as outcomes) adjusted for age and gender (Model 1), and additionally adjusted for body 595 
mass index, smoking status, prevalent diseases, systolic blood pressure, non-fasting glucose, total 596 
cholesterol, index1(time), energy intake, income, alcohol, statin use (Model 2a). For 597 
adipocytokines, model 2 was further adjusted for C-reactive protein (Model 2b). Additional 598 
adjustment for other covariates did not change the effect estimate with >10%. 599 
600 
 Model 1 
β (95% CI) 
Model 2 
β (95%CI) 
CRP§ (N=4507) 0.001 (-0.004,0.007) -0.002(-0.007,0.003)a 
Leptin§ (N=798) -0.012 (-0.023, -0.001) -0.009(-0.017, -0.00005)b 
Adiponectin§ (N=798) 0.009 (0.002,0.015)* 0.009(0.003,0.016)*b 
PAI-1§ (N=798) -0.018(-0.028, -0.008)* -0.018(-0.027, -0.008)*b 
Resistin§ (N= 798) 0.002 (-0.006,0.009) 0.001(-0.006,0.009)b 
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Table 3 Association of uric acid and gamma glutamyltransferase with C-reactive protein and 601 
adipocytokines: the Rotterdam study. 602 
 Uric acid (per SD) GGT (per SD)§ 
 Model 1 




β (95% CI) 
Model 2 









































CI, confidence interval; CRP, C-reactive protein; GGT, gamma glutamyltransferase; PAI-1, 603 
Plasminogen Activator Inhibitor-1; SD, standard deviation. 604 
§ Variables were log transformed to better approximate normal distribution. 605 
* remains significant after Bonferroni correction (p=0.0166) 606 
βs and 95% confidence intervals were estimated using generalized estimated equations (for C-607 
reactive protein as outcome) and linear regression models (for leptin, adiponectin, PAI-1 and 608 
resistin as outcomes) adjusted for age and sex (Model 1) and additionally adjusted for baseline 609 
body mass time, time of measurement, non-fasting glucose, energy intake,  total cholesterol, 610 
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hormone replacement therapy, systolic blood pressure, diastolic blood pressure, statin use, 611 
income, alcohol+ GGT/uric acid (adjustment for GGT when uric acid was the exposure and vice 612 
versa) (Model 2a). For adipocytokines as outcomes, model 2 was further adjusted for baseline C-613 
reactive protein (Model 2b). Results are presented per standard deviation uric acid (for CRP as 614 
outcome: 1SD= 80.5611 µmol/L; for adipocytokines as outcome: 1SD=73,1832 µmol/L) and 615 
GGT levels (for CRP as outcome: 1SD=29,9731 U/L ; for adipocytokines as outcome: 616 
1SD=22,4034 U/L).  617 
 618 
 619 
